KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Equity Average (2016 - 2025)

Historic Equity Average for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Q4 2025 value amounting to $18.0 billion.

  • Vertex Pharmaceuticals' Equity Average rose 1230.97% to $18.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $18.0 billion, marking a year-over-year increase of 1230.97%. This contributed to the annual value of $17.5 billion for FY2025, which is 319.33% up from last year.
  • Vertex Pharmaceuticals' Equity Average amounted to $18.0 billion in Q4 2025, which was up 1230.97% from $17.2 billion recorded in Q3 2025.
  • Vertex Pharmaceuticals' Equity Average's 5-year high stood at $18.1 billion during Q1 2024, with a 5-year trough of $8.8 billion in Q1 2021.
  • For the 5-year period, Vertex Pharmaceuticals' Equity Average averaged around $14.1 billion, with its median value being $15.1 billion (2023).
  • Its Equity Average has fluctuated over the past 5 years, first soared by 4080.9% in 2021, then tumbled by 891.6% in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Equity Average stood at $9.8 billion in 2021, then surged by 37.25% to $13.5 billion in 2022, then rose by 26.54% to $17.0 billion in 2023, then dropped by 6.02% to $16.0 billion in 2024, then rose by 12.31% to $18.0 billion in 2025.
  • Its Equity Average stands at $18.0 billion for Q4 2025, versus $17.2 billion for Q3 2025 and $16.8 billion for Q2 2025.